Quintiles lays off staffers in shift to emerging markets

The big CRO Quintiles laid off an unspecified number of workers late last week, acknowledging a "slight shift" of clinical trial work toward emerging markets. A company spokesperson declined to say just how many workers were pink slipped, but said it amounted to fewer than the number of open jobs it currently lists (about 350). Altogether Quintiles has about 20,000 workers in 60 countries, with 1,400 employed at its headquarters in Research Triangle Park. Story

Suggested Articles

Versantis will use the €16 million to trial a drug designed to remove toxic metabolites from liver disease patients.

The Merck-backed round positions Themis to take its chikungunya vaccine through phase 3 and start testing a cancer drug in humans.

No biohazardous substances were in the room where the explosion happened, according to the Russian virology center.